Addition of probenecid to penicillin-V therapy

  • Research type

    Research Study

  • Full title

    Addition of probenecid to penicillin-V therapy: an open label, cross-over study in healthy volunteers

  • IRAS ID

    299581

  • Contact name

    Timothy Rawson

  • Contact email

    tmr07@ic.ac.uk

  • Sponsor organisation

    Research Governance and Integrity Team (RGIT)

  • Eudract number

    2021-002800-11

  • Clinicaltrials.gov Identifier

    NCT05082909

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    This study aims to build on previous work characterising the PK of penicillin-V to explore the potential impact of probenecid on PK-PD target attainment. Achievement of the aims of this study would provide data to support the design of experimental studies exploring the clinical impact of probenecid on treatment outcomes and also provide a rationale for exploration of probenecid’s effects on a larger number of beta-lactam antibiotics.

    Hypothesis: Addition of probenecid to oral phenoxymethylpenicillin (penicillin-V) has a clinically relevant effect on pharmacokinetic-pharmacodynamic (PK-PD) target attainment.

    Study design: Open label, cross-over study in healthy volunteers that will take place at Imperial Clinical Research Facility (CRF), Hammersmith Hospital, Du Cane Road, W12 0NN.

    Healthy volunteers will attend two visits to Imperial CRF to undergo blood test analysis following dosing with either oral penicillin-V or oral penicillin-V plus probenecid. The effect of probenecid on penicillin-V serum concentration will be compared between both arms of the study.

    Funding: This study is funded a British Infection Association (BIA) research grant.

  • REC name

    London - Riverside Research Ethics Committee

  • REC reference

    21/LO/0558

  • Date of REC Opinion

    10 Aug 2021

  • REC opinion

    Favourable Opinion